Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Optimizing COVID-19 Booster Shot Usage: A New Sheba Study

COVID-19 Booster Shot
With a new indication regarding the efficacy period of the fourth COVID-19 shots, it is clear that their administration, and that of future boosters, must be timed properly

A new Sheba study involving first-generation Pfizer COVID-19 vaccines, published in the New England Journal of Medicine, showed that the fourth vaccine dose increased antibody levels for only around 13 weeks. 

Conducted by Sheba researchers alongside experts from the Israeli Health Ministry and Columbia University researchers, the study comprised over 6,000 Sheba employees and volunteers.

Based on the findings, Sheba researchers suggest healthcare providers should plan booster shot administration carefully, as added protection against infection peaks for a relatively short period, i.e., boosters should be given when episodes of high infection are expected or when specific patients face circumstances that make them more prone to infection and serious disease. 

According to Prof. Regev-Yochay, Director of the Infectious Prevention and Control Unit at Sheba and one of the study’s lead authors, it is necessary to “take into consideration not only surges in infection, but also personal medical conditions, upcoming events, travel plans, and high risk periods.”

While it remains unclear how antibody levels correlate with protection against serious illness, the study did not examine the possibility that the vaccine may offer protection against severe forms of the disease for longer than three months, the period in which antibody levels are high.

News Mar 26.
West Bank and Gaza Medical Professionals Attend a Milestone Sheba Oncology Conference
Highlighting the latest in cancer care, with a particular focus on pediatrics, the Recent Advances in Cancer Care (REACT) 2023 event was attended by over…
Read More
Isenia’s Battle
Isenia’s Battle with Alveolar Sarcoma
At 17, Isenia, a native of Semey, Kazakhstan, noticed a lump on her leg the size of a small apple. Initially, Isenia and her family…
Read More
Colon and Rectal Cancer
News Mar 14.
Sheba Study Indicates Readily-Available Drugs May Prevent Metastasis in Colon and Rectal Cancer Patients
Favorable responses to the treatment were noted by Prof. Shamgar Ben-Eliyahu, a neuroscientist specializing in psychoneuroimmunology (PNI) at TAU’s Sagol School of Neuroscience and School…
Read More